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Background: Adiponectin has been reported as a new risk factor for the development of diabetes.
However, it is not clear whether adiponectin levels are associated with family history of diabetes (FHD).
Objective: The objective of this study was to measure the independent association of serum adiponectin
with FHD in relation to insulin resistance and obesity.
Methods: In 2006, a cross-sectional study was conducted in which waist circumference (WC), body
mass index (BMI), and serum adiponectin were measured in 5919 healthy Korean men and women.
Multiple linear regression models were used to assess the association of serum adiponectin levels with
FHD. The population was classified into two groups according to median values for each of the
following variables: WC, BMI, and homeostasis model assessment of insulin resistance (HOMA-IR).
Results: The positive FHD group had higher HOMA-IR and lower adiponectin levels in both men and
women than those without FHD. Adiponectin levels were significantly associated with FHD in men and
women respectively, after adjusting for age, BMI, and alcohol consumption (PZ0.0123 and 0.0004).
The relationship between adiponectin and FHD was similar between the high and low insulin
resistance, BMI, and WC groups in male non-smokers and in all Korean women.
Conclusion: These results confirm that adiponectin levels are associated with FHD. These data also
suggest that the association of serum adiponectin with FHD may be independent of obesity and insulin
resistance.
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Adiponectin has been reported as a new risk factor for the
development of diabetes. Exclusively secreted by adipose
tissue, ADIPOQ is a 244-amino acid protein that regulates
the metabolism of lipids and glucose, and circulates quite
abundantly in plasma (1–5). ADIPOQ decreases insulin
resistanceandbodyweight by increasing lipid oxidation in
muscle and other organs such as the pancreas and liver
(6). Plasma ADIPOQ concentrations are also reduced in
individuals with obesity, diabetes mellitus, or coronary
heart disease (7, 8).
Family history of diabetes (FHD) has been associated
with hypoadiponectinemia in some (9–13) but not all
studies (14–16). However, previous studies generally
had small sample sizes that may explain the incon-
sistencies in findings. The underlying mechanisms of
association between FHD and ADIPOQ levels are not yet
fully understood. Because ADIPOQ levels can be used to
predict increased insulin sensitivity (14), the inversendocrinologyassociation between ADIPOQ and FHD may be due to
insulin resistance (14, 17). However, the literature on
the association of serum ADIPOQ levels with FHD
independently of insulin resistance is sparse. Thus, the
purpose of this study was to see whether the association
between FHD and ADIPOQ levels in relation to insulin
resistance and obesity is independent.Materials and methods
Study subjects
The study population comprised 6551 subjects who
participated in the Korean Metabolic Syndrome
Research Initiative and had routine health exami-
nations at the Health Promotion Center in University
Hospitals from January to December 2006. The
objective and contents of this research project were
explained to participants who volunteered to undergo
the health examinations. Recruitment of theseDOI: 10.1530/EJE-08-0603
Online version via www.eje-online.org
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consent had been obtained. Participating hospitals are
listed in the appendix (18). The analysis excluded
subjects with missing information on waist circumfer-
ence (WC), body mass index (BMI), or ADIPOQ levels,
and those who had a history of cancer, cardiovascular
disease, stroke, or diabetes (nZ292). We also excluded
those who had been on medication for diabetes and
subjects with a fasting blood sugarO110 mg/dl
(nZ340). Finally, 5919 subjects, aged between 24
and 87 years were selected for subsequent analysis. The
Institutional Review Board of Human Research of
Yonsei University approved the study, and written
informed consent was obtained from all subjects.Data collection
Each participant was interviewed using a structured
questionnaire to collect the history of cigarette smoking
(never smoked, ex-smoker, or current smoker) andalcohol
consumption (non-drinker or drinker of any amount of
alcohol), as well as other demographic characteristics
suchas age, gender, and FHD. FHDwas defined as subjects
with at least one first-degree relativewith diabetes (parent
or sibling). Both current and ex-smokers were asked to
report the averagenumber of cigarettes they smoke orhad
smoked per day. WC was measured midway between the
lower rib and the iliac crest. Weight and height were
measured while the participants were wearing light
clothing. BMI was calculated as weight (kg) divided by
the square of height (m2). Blood pressure was measured
for the patient in a seated position by a registered nurse or
blood pressure technician using a standard mercury
sphygmomanometer or automatic manometer. Both
systolic and diastolic blood pressures were measured
after a 15-min rest.Measurement of biomarkers
For the clinical chemistry assay, serum was separated
from peripheral venous blood samples that were
obtained from each participant after 12 h of fasting,
and was stored atK70 8C for 2 h. Metabolic syndrome
biomarkers such as fasting blood glucose, total
cholesterol (TC), triglycerides (TG), and high density
lipoprotein cholesterol (HDL-C) were measured using
the Hitachi-7600 analyzer (Hitachi Ltd). For subjects
with serum available, ADIPOQ levels were measured
using an ELISA (Mesdia Co., Ltd, Seoul, Republic of
Korea) (18). Insulin resistance was calculated using the
homeostasis model assessment of insulin resistance
(HOMA-IR). HOMA indices were calculated as follows:
HOMAZfasting insulin (mlU/ml)!fasting glucose
(mmol/l)/22.5. The intra- and interassay variances for
the ADIPOQ were 6.3–7.4% and 4.5–8.6% respectively.
Data quality control was performed in accordance with
the procedures of the Korean Association of Laboratory
Quality Control.www.eje-online.orgStatistical analysis
All biomarkers except ADIPOQ were found to have a
normal distribution. Therefore, ADIPOQ levels are
presented as median interquartile range and were log-
transformed in the multivariate analyses. The indepen-
dent t-test was used to analyze the statistical differences
among the characteristics of the study participants. The
mean serum ADIPOQ level was calculated for each
category of FHD. Multiple linear regression models were
used to assess the associations of serum ADIPOQ levels
with FHD. Current smokers were further divided into
two groups of 1–10 and 10 and more cigarettes per day.
Analyses were adjusted for age at enrollment (continu-
ous variable), BMI, and smoking status.
To examine the association between FHD and
ADIPOQ stratified by insulin resistance (HOMA-IR),
BMI, and WC, we divided our study samples into two
groups (by median values) of HOMA-IR (!0.795 and
R0.795), BMI (!24.48 and R24.48), and WC (!85
and R8) for men and HOMA-IR (!0.705 and
R0.705), BMI (!22.3 and R22.3), and WC (!74.5
and R74.5) for women. All analyses were conducted
using SAS statistical software, version 9.0 (SAS Institute
Inc, Cary, NC, USA). All statistical tests were two-sided,
and statistical significance was determined as P!0.05.Results
The characteristics of participants in relation to their
FHD are shown for Koreanmen in Table 1. Male subjects
with FHD were on average younger than those without
FHD. In general, those with FHD had higher WC, BMI,
FBS, TC, HOMA, and insulin levels, and had lower
ADIPOQ levels. However, HDL cholesterol, C-reactive
protein (CRP), and smoking status were similar for the
two groups. For women, subjects with FHD were also on
average younger than those without FHD (Table 2).
Those with FHD generally had higher FBS and HOMA
levels, and women with FHD had lower ADIPOQ levels.
However, WC, BMI, HDL cholesterol, and CRP measure-
ments were similar for the two groups (Table 2).
Using the age-adjusted Pearson correlation test, levels
of ADIPOQ were found to be inversely associated with
BMI, WC, and TG, and directly associated with HDL
cholesterol (P!0.001).However, the correlationbetween
CRP and ADIPOQ was not significant (PZ0.3228; data
not shown). ADIPOQ levels were significantly associated
with FHD in men and women respectively, after adjusting
for age, BMI, and alcohol drinking (PZ0.0123 and
0.0004; Table 3). When HOMA index was added as a
covariate, the association didn’t changemuch inmenand
women (PZ0.0177 and 0.0004; data not shown).
To control for potential confounding by insulin
resistance and obesity, data were further stratified by
BMI,WC, and HOMA (Table 4). For men, the relationship
between ADIPOQ and FHD was statistically significant in
Table 1 General characteristics of healthy Korean men according
to family history of diabetes.
Family history of diabetes
Negative
(NZ2825)
Positive
(NZ503)
N MeanGS.D. MeanGS.D. P value
Age (year) 45.7G9.3 43.4G7.3 !0.0001
WC (cm) 84.9G7.2 86.0G7.4 0.0022
BMI (kg/m2) 24.5G2.6 24.9G2.8 0.0038
ADIPOQa (mg/ml) 6.20G4.7 5.65G4.1 0.0005
Log ADIPOQa 2.52G0.8 2.42G0.7 0.0006
FBS (mg/dl) 90.5G8.3 92.6G8.5 !0.0001
SBP (mmHg) 123.0G13.6 123.5G11.9 0.4353
DBP (mmHg) 77.9G10.8 77.6G10.4 0.6599
Total cholesterol (mg/dl) 186.8G30.2 191.0G30.9 0.0046
HDL cholesterol (mg/dl) 49.9G11.0 49.6G10.9 0.5934
LDL cholesterol (mg/dl) 115.5G28.2 117.5G28.2 0.2117
Triglyceride (mg/dl) 142.1G92.3 149.6G101.9 0.1004
C-reactive protein (mg/dl) 0.16G0.3 0.16G0.3 0.9726
HOMA 0.93G0.7 1.02G0.7 0.0067
Insulin (mIU/ml) 4.12G2.9 4.41G2.8 0.0316
Smoking status (%)
Ex 34.8 33.2 0.3663
Current 40.0 38.6
Alcohol drinking (%) 88.5 89.5 0.5433
P values refer to differences between groups as determined by t-test and c2-
test for continuous and categorical variables respectively. FBS, fasting
plasma glucose; BMI, body mass index; WC, waist circumference; SBP,
systolic blood pressure; DBP, diastolic blood pressure; HOMA, homeostasis
model assessment; HDL, high density lipoprotein; LDL, low density
lipoprotein.
aMedianGinterquartile range (IQR).
Table 2 General characteristics of healthy Korean women
according to family history of diabetes.
Family history of diabetes
Negative
(NZ2141)
Positive
(NZ450)
N MeanGS.D. MeanGS.D. P value
Age (year) 44.4G9.5 43.2G7.9 0.0033
Waist (cm) 74.9G7.8 75.3G7.9 0.3777
BMI (kg/m2) 22.7G2.9 22.8G2.8 0.5237
ADIPOQa (mg/ml) 10.0G7.4 8.7G6.7 0.0001
Log ADIPOQa 3.0G0.7 2.9G0.7 !0.0001
FBS (mg/dl) 86.6G7.9 89.2G8.3 !0.0001
SBP (mmHg) 115.2G13.8 116.1G14.6 0.2343
DBP (mmHg) 71.7G10.2 71.6G10.5 0.9820
Total cholesterol (mg/dl) 182.3G32.9 181.6G30.3 0.6440
HDL cholesterol (mg/dl) 59.5G13.0 58.8G12.2 0.2755
LDL cholesterol (mg/dl) 108.5G30.4 105.7G27.5 0.0597
Triglyceride (mg/dl) 90.6G52.7 89.3G51.1 0.6369
C-reactive protein (mg/dl) 0.12G0.2 0.11G0.2 0.6152
HOMA 0.81G0.6 0.88G0.6 0.0386
Insulin (mIU/ml) 3.75G2.6 3.93G2.5 0.1795
Smoking status (%)
Ex 2.5 1.8 0.1034
Current 4.1 2.2
Alcohol drinking (%) 51.2 52.8 0.5124
P values refer to differences between groups as determined by t-test and c2-
test for continuous and categorical variables respectively. FBS, fasting
plasma glucose; BMI, body mass index; WC, waist circumference; SBP,
systolic blood pressure; DBP, diastolic blood pressure; HOMA, homeostasis
model assessment; HDL, high density lipoprotein; LDL, low density
lipoprotein.
aMedianGinterquartile range (IQR).
Table 3 Multiple linear regression model of mean log ADIPOQ in
healthy Korean men and women.
Model 1 Model 2
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non-smokers, while this relationship was not significant
in the other groups (Table 4). However,when the analyses
were performed only on non-smokers and light smokers,
ADIPOQ levels were significantly associated with FHD in
bothBMI groups. TheWCandHOMAgroups also showed
similar associations of ADIPOQ levels with FHD.
For women, ADIPOQ levels in the FHD group were
significantly lower among those with HOMA!0.705 (P
valueZ0.0377) and with HOMAR0.705 (P valueZ
0.0036) respectively, compared with the non-FHD
group (Table 4). Similar associations of ADIPOQ levels
with FHD were seen in the BMI and WC groups.Variables b P value b P value
Men
Age (year) 0.007 !0.0001 0.005 !0.0001
Family history of
diabetes
K0.077 0.0042 K0.066 0.0123
BMI (kg/m2) K0.040 !0.0001
Smoking status
Ex K0.007 0.7881
Current K0.076 0.0017
Women
Age (year) 0.005 0.0001 0.009 !0.0001
Family history of
diabetes
K0.113 0.0001 K0.103 0.0004
BMI (kg/m2) K0.037 !0.0001
Smoking status
Ex 0.104 0.1511
Current 0.037 0.5274Discussion
Our study demonstrates that FHD is associated with
hypoadiponectinemia that supports findings of previous
studies (9, 10). In a recent study, in 64-year-old women
in Sweden, mean ADIPOQ levels were lower (11.4 vs
13.9) in those with FHD than those without FHD (10).
In another study in male subjects in Sweden, first-
degree relatives of type 2 diabetic patients also had
significantly lower ADIPOQ levels (9). The present study
showed an inverse relationship between FHD and
ADIPOQ levels in Korean men and women. For men,
the association was stronger in non-smokers whichimplies that smoking is a confounding factor. Moreover,
in male non-smokers and in Korean women, the
relationship remained even when performing subgroup
analyses of the HOMA-IR, BMI, and WC categories,
suggesting that the association of serum ADIPOQ with
FHD is independent of obesity and insulin resistance.
The present study was performed with a larger sample
size than that of other studies, and like these previouswww.eje-online.org
Table 4 Multiple linear regression modela of mean log ADIPOQ for family history of diabetes (yes) by BMI, WC, and HOMA in healthy
Korean men and women.
All men FHD
(yes)
Non or light smoking men FHD
(yes)
All women FHD
(yes)
Variables Subgroups N b P value N b P value N b P value
BMI (kg/m2) !24.48 1666 K0.083 0.0359 549 K0.140 0.0225 1292 K0.122 0.0036
R24.48 1662 K0.054 0.1308 488 K0.134 0.0384 1299 K0.084 0.0375
WC (cm) !85 1574 K0.046 0.2502 525 K0.114 0.0436 1334 K0.066 0.1070
R85 1754 K0.072 0.0427 512 K0.140 0.0308 1257 K0.143 0.0006
HOMA !0.795 1664 K0.057 0.1450 534 K0.156 0.0170 1297 K0.090 0.0377
R0.795 1664 K0.065 0.0704 503 K0.101 0.0934 1294 K0.115 0.0036
Adjusted for age, BMI, and alcohol drinking. BMI, body mass index; WC, waist circumference; HOMA, homeostasis model assessment; FHD, family history of
diabetes; light smokers, subjects who smoke !10 cigarettes per day.
aReference group: no family history of diabetes groups.
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concentrations in FHD groups were not dependent on
insulin resistance status or obesity. Because ADIPOQ
predicts increased insulin sensitivity (14), the inverse
association between ADIPOQ and obesity, T2DM, or FHD
may to a large extent, be explained by the parallel
occurrence of insulin resistance (14, 17). However, a
recent cross-sectional study in Sweden reported that a
FHD was associated with low serum ADIPOQ concen-
trations independently of obesity, glycemia, or insulin
sensitivity, although the study was limited by the fact that
all of the study subjects were 64-year-old women (10).
Two other studies have reported that ADIPOQ levels are
reduced in lean offspring of type 2 diabetes subjects
maintaining that the inverse association ofADIPOQ levels
with FHD is independent of BMI (9, 12).
We observed a sex difference in the association of
ADIPOQ with FHD in this Korean population. Women
showed a stronger association of ADIPOQ with FHD than
did men. One of the possible reasons of the difference is a
clear difference in TG concentration between men and
women in the present study. Serumtriglyceride levelswere
much higher in men than in women. However, mean TG
levels were significantly lower in male non-smokers than
in male current smokers (119.2 and 151.3 mg/dl; data
not shown).When theanalyseswereperformedaccording
to smoking status inmen, the association ofADIPOQwith
FHD appeared stronger in non-smokers. This observation
along with recent studies which have reported that
smoking status is associated with lower levels of ADIPOQ
(19–21), suggests that smoking is a possible confounder
in the associationbetweenADIPOQandFHD.The possible
causes of sex differences in the association of ADIPOQ
levels with FHD should be investigated further.
This study has several limitations. Due to its cross-
sectional design, this study cannot elucidate mech-
anisms or determine the direction of causality of
the relationship between ADIPOQ and FHD. A single
assessment of ADIPOQ levels may be susceptible to
short-term variation, which would bias the results
toward the null. However, Pischon et al. reported that
intra-individual ADIPOQ levels are reasonably stable
over time, with an intra-class correlation coefficient ofwww.eje-online.org0.85 for ADIPOQ levels measured within the same
participants 1 year apart (22). Another limitation of
this study is the classification of FHD. We did not
classify the types of diabetes. However, type 2 diabetes
is the most common type of diabetes in the Republic of
Korea, while the incidence rate of type 1 diabetes in
the country is among the lowest reported in the world.
During the period 1995–2000, the age-adjusted
incidence of type 1 diabetes was 1.36 per
100 000/year (23, 24).
In summary, these results confirm that ADIPOQ
concentrations are lower in first-degree relatives of
diabetic patients, and suggest that the association may
not be due to the concomitant presence of insulin
resistance and obesity. Further studies should be
performed in other populations to confirm the associ-
ation between ADIPOQ and FHD regardless of insulin
resistance.Declaration of interest
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